Recommended
Recommended
More Related Content
Similar to Innovate for health csem 17.09.2014xxx
Similar to Innovate for health csem 17.09.2014xxx (20)
Recently uploaded
Recently uploaded (20)
Innovate for health csem 17.09.2014xxx
- 1. Click to edit Master title style 11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 1 © BD, ROI © 2013 IBM Corporation Biotech, Medtech and Bioconvergence Dr. Benoit Dubuis, President BioAlps & Inartis-Network, Executive Director Campus Biotech 17.09.2014
- 2. HEALTH CARE “Medical revolution and new technologies” The challenges Towards bioconvergence Our contribution Anticipate the Future
- 3. HEALTH CARE “Medical revolution and new technologies” The challenges Towards bioconvergence Our contribution Anticipate the Future
- 4. Crossing Visions 19/09/14 | 4 MAJOR CHALLENGES IN HEALTHCARE Therapeutic challenges Demographics Cost Access Variation in clinical practice Inefficient use of information Fragmented care versus integrated care Duplication, defensive medicine & waste Protracted adoption of innovation
- 5. Crossing Visions 19/09/14 | 5 CAUSES OF DEATH
- 6. DEMOGRAPHICS: WE LIVE LONGER 2 Crossing Visions 19/09/14 | 6 Life Expectancy at Birth CH: 84.7 1900 1950 2010 2050 Benchmark: Life expectancy in imperial Rome was ~ 30 years CH: 80.5 Age 60 – 2 Billion Age 80 – 380 Million Age 100 – 2 Million
- 7. Crossing Visions 19/09/14 | 7 HEALTH CARE COSTS 3
- 8. Crossing Visions 19/09/14 | 8 THE BURDEN OF CHRONIC DISEASES Healthcare spending for people with chronic conditions Nearly half of us will have chronic conditions by 2030: Diabetes Neurodegenerative Disease Obesity Hypertension Arthritis Atherosclerosis Stroke Cancer Degenerative Joint disease Degenerative Spine Disease Obstructive Lung Disease Healthcare spending for people without chronic conditions Chronic conditions account for 83% of health care 4spending
- 9. NEW NEEDS IN NEURO-ENGINEERING 5
- 10. Crossing Visions 19/09/14 | 10 TOWARD HEALTHIER LIFE Past model Healthy life Present model Healthy life Compressed morbidity model Disease Disability Disease Disability Healthy life DiseLaisfee years gained Disability
- 11. Click to edit Master title style MEDTECH “Medical revolution and new technologies” The challenges Towards Bioconvergence Our contribution Anticipate the Future 11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 11
- 12. Crossing Visions 19/09/14 | 12 CHANGING FOCUS ON HEALTH CARE Technology convergence Pharmacogenomics 3P medicine Translational medicine Wireless Health
- 13. TOWARDS AN INTEGRATED HEALTH SYSTEM Rx 2009
- 14. INNOVATION BY BIOCONVERGENCE Crossing Visions 19/09/14 | 14
- 15. Crossing Visions 19/09/14 | 15 EXPLORE INTERFACES
- 16. Crossing Visions 19/09/14 | 16 NEXT GENERATION PLATFORM TECHNOLOGIES NEW PRODUCTS NEW SOLUTIONS
- 17. Crossing Visions 19/09/14 | 18 THE STRENGTH OF THE NETWORK CLINICAL CENTERS ACADEMIC CENTERS CORE FACILITIES INDUSTRY START-UPS
- 18. Interdisciplinarity (science driven) 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 19
- 19. What is a Stent A small, mesh-like device made of metal Acts as a support or scaffold, in keeping the vessel open Stent helps to improve blood flow to the heart muscle and reduce the pain of angina 80% of patients who have balloon angioplasty will have a stent placed as well.
- 20. History Percutaneous transluminal coronary angioplasty (PTCA) by Gruntzig in 1977 Puel and Sigwart, in 1986, deployed the first coronary stent to act as a scaffold In 2001, drug-eluting stents (DES) were introduced as a strategy to minimize restenosis
- 21. Types Bare metal stents: Traditional method May have an increased rate of re-narrowing due to growth of scar tissue in the stent, a condition called Restenosis. Drug-eluting stents: Combat Restenosis Coated with medications that are slowly released to block the body's ability to form scar tissue around the stent. The medication is delivered directly to the site of the artery blockage.
- 22. Click to edit Master title style MEDTECH “Medical revolution and new technologies” The challenges Towards an integrated health system Our contribution Innovation: The New Currency of Competition 11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 23
- 23. Crossing Visions 19/09/14 | 24 MICRO / NANO CLUSTER BIOCLUSTER A UNIQUE HUB FOR MEDTECH & BIOTECH
- 24. WORLD-CLASS ACADEMIC INSTITUTIONS Generate Knowledge Create Opportunities
- 25. Access to tools and knowledge 'evolutionary developmental biology' Electronic health record' 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 26
- 26. The shift to patient-empowering, information-leveraging technologies “PI” (patient-empowering and information-leveraging) technologies 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 27
- 27. Genomic & physiology Molecular and personalized medicine Proficient use of Information (e.health) Access, Cost and Quality of care 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 29
- 28. INNOVATION The New Currency of Competition 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 30
- 29. EXPLORE NEW AVENUES 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 31
- 30. WHERE Towards HISTORY WRITES Campus Biotech 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 32
- 31. WHERE ENSURING THAT HISTORY HISTORY GOES WRITES ON 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 33
- 33. NEW PATHS Crossing Visions 19/09/14 | 35
- 34. 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 36
- 35. ACCELERATE TECH TRANSFER 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 37
- 36. Support Technology Transfer 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 38
- 37. INARTIS NETWORK, NTN R&D Projects R&D Projects (CTI) (CTI) Workshops Events Workshops Events NNeetwtwoorkrikningg 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 39
- 38. Click to edit Master title style MEDTECH “Medical revolution and new technologies” The challenges Towards an integrated health system Our contribution Anticipate the Future 11.6.2013 IBM Technology Day 2013, Keynote B. Dubuis 40
- 39. 750 companties 25’000 employees Crossing Visions 19/09/14 | 41
- 40. Crossing Visions 19/09/14 | 42 Support the growth Anticipate the Future Vitesse moyenne de croissance annuelle 95-00, 00-06 Source: BAK, Basel Economics
- 41. A Successfull biocluster Established access to Capital Experienced Business and Law Firms Carve-Outs/ Spinouts Experienced Entrepreneur Innovation Initiatives World-Class Research Institutions World-Class Business Schools Experienced Technical People IP Create Value around IP PhD’s MBA’s Early-Stage Company Late-Stage Emerging/Public Public Industry Leader C://DUBUIS, 2009 1/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis 43
- 42. © 2014 INARTIS © 2013 IBM Corporation Find the slides on: www.republic-of-innovation.ch Dr. Benoit Dubuis bd@republic-of-innovation.ch
Editor's Notes
- Charting the shift The accompanying chart shows several existing technologies clustered along two dimensions: whether they are providercontrolled or patient-empowering (on the vertical axis) and the extent to which they are information-leveraging (on the horizontal axis). Historically, the majority of medical technologies have not leveraged information. Some of these products have been targeted at patients (such as contact lenses and hearing aids — shown in Quadrant 2). Other products have been marketed to both patients and physicians (syringes, thermometers, bandages, etc.). But so far, the vast majority of medical technologies have been in Quadrant 1 — products that did not leverage information and were controlled by providers. More and more products are migrating away from Quadrant 1. In some cases, products have started leveraging information even though they are still under the control of providers (e.g., smart beds, which are remaking the lowly hospital bed into a device that can generate and track all sorts of useful health data). In other cases, the initial move was to become more patientempowering even though products still did not leverage information (e.g., traditional blood-pressure cuffs). Over time, however, many of these products will end up squarely in Quadrant 4 — effectively becoming PI technologies. While the blood-pressure monitors that initially moved into patients’ hands may not have been information-leveraging, the most recent iterations certainly are. Indeed, entire classes of diagnostic equipment — from blood-pressure monitors to glucometers and the aforementioned Cardiio heart-rate monitor — are being reinvented in radically patient-friendly ways. Many of these technologies are minimally invasive, compatible with consumer technologies such as smartphones and tablets, and allow patients to track, analyze and learn from their own data. Apnea monitors, for instance, have long been information-leveraging, but they were entirely controlled by providers. Now, sensor-embedded consumer devices such as the Zeo Sleep Manager allow patients to monitor their sleep every day. This gives apnea patients not only ownership over their data, but also more useful data — information that is generated in real-world conditions and provides a longitudinal panel from which to extract true insights into the behaviors and factors that exacerbate one’s ailment. The movement is gaining steam. While many categories of products will likely always remain in hospitals or under the control of physicians, in other categories — diagnostics, monitoring equipment, even some types of imaging products — we are likely to see more and more products empowering patients and leveraging information. The shift is likely to be accelerated not just by the pace of technological innovation, but also by the huge challenges facing health care and the fact that PI technologies can play a critical role in addressing these challenges.